What is it used for?
ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- elranatamabelranatamab
- Form and strength
- INJECTION, SOLUTION · 44 mg / 1.1 mL; INJECTION, SOLUTION · 76 mg / 1.9 mLINJECTION, SOLUTION · 44 mg / 1.1 mL; INJECTION, SOLUTION · 76 mg / 1.9 mL
- Manufacturer / applicant
- PFIZER LABORATORIES DIV PFIZER INCPFIZER LABORATORIES DIV PFIZER INC
ELREXFIO injection is a clear to slightly opalescent, and colorless to pale brown liquid solution available as: •76 mg/1.9 mL (40 mg/mL) in a single-dose vial •44 mg/1.1 mL (40 mg/mL) in a single-dose vialELREXFIO injection is a clear to slightly opalescent, and colorless to pale brown liquid solution available as: •76 mg/1.9 mL (40 mg/mL) in a single-dose vial •44 mg/1.1 mL (40 mg/mL) in a single-dose vial
Safety and clinical review
• Cytokine Release Syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving ELREXFIO. Initiate treatment with ELREXFIO step-up dosing schedule to reduce the risk of CRS. Withhold ELREXFIO until CRS resolves or permanently discontinue based on severity . • …• Cytokine Release Syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving ELREXFIO. Initiate treatment with ELREXFIO step-up dosing schedule to reduce the risk of CRS. Withhold ELREXFIO until CRS resolves or permanently discontinue based on severity . • …
- Cytokine Release Syndrome (CRS)Cytokine Release Syndrome (CRS)
- Neurologic Toxicity, Including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)Neurologic Toxicity, Including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
- ELREXFIO REMSELREXFIO REMS
- InfectionsInfections
- NeutropeniaNeutropenia
- HepatotoxicityHepatotoxicity
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is ELREXFIO used for?
ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of ELREXFIO should I ask about?
INJECTION, SOLUTION · 44 mg / 1.1 mL; INJECTION, SOLUTION · 76 mg / 1.9 mLINJECTION, SOLUTION · 44 mg / 1.1 mL; INJECTION, SOLUTION · 76 mg / 1.9 mL
Read the primary sourceWhat determines the price of ELREXFIO?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using ELREXFIO?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
FDA prescribing informationThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.